{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:08:00Z","timestamp":1789520880327,"version":"build-2803163510"},"reference-count":118,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2025AFB501"],"award-info":[{"award-number":["2025AFB501"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbcan.2026.189637","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:15:24Z","timestamp":1784387724000},"page":"189637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current status, prospects, and challenges of cell therapy for urological tumors"],"prefix":"10.1016","volume":"1881","author":[{"given":"Ju","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbcan.2026.189637_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189637_bb0010","first-page":"105","article-title":"Overview of perspectives on cancer, newer therapies, and future directions","volume":"10","author":"Joshi","year":"2024","journal-title":"Oncol. Transl. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189637_bb0015","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189637_bb0020","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0025","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/JS9.0000000000001999","article-title":"Correlation of noninvasive imaging of tumor-infiltrating lymphocytes with survival and BCG immunotherapy response in patients with bladder cancer: a multicentre cohort study","volume":"111","author":"Chen","year":"2025","journal-title":"Int. J. Surg."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pros.24068","article-title":"High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy","volume":"81","author":"Yang","year":"2020","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189637_bb0035","article-title":"Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma","volume":"4","author":"Deutsch","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189637_bb0040","doi-asserted-by":"crossref","first-page":"9291","DOI":"10.1002\/jcp.29827","article-title":"Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy","volume":"235","author":"Zhang","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189637_bb0045","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3390\/cancers12092471","article-title":"Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189637_bb0050","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1158\/1078-0432.CCR-22-2428","article-title":"TIL therapy: facts and hopes","volume":"29","author":"Monberg","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189637_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0060","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2414542","article-title":"Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization","volume":"20","author":"Hori","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189637_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009147","article-title":"Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus","volume":"12","author":"Barisic","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189637_bb0070","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00262-019-02419-4","article-title":"Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma","volume":"68","author":"Xu","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189637_bb0075","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.it.2017.12.001","article-title":"Natural killer cell education and the response to infection and cancer therapy: stay tuned","volume":"39","author":"Boudreau","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbcan.2026.189637_bb0080","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","article-title":"NK cell metabolism and tumor microenvironment","volume":"10","author":"Terr\u00e9n","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189637_bb0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189637_bb0090","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbcan.2026.189637_bb0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0100","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2379086","article-title":"Vaccine approaches to treat urothelial cancer","volume":"20","author":"Giudice","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.bbcan.2026.189637_bb0110","article-title":"Engineered anti-prostate cancer CAR-neutrophils from human pluripotent stem cells","volume":"20","author":"Harris","year":"2023","journal-title":"J. Immunol. Regen. Med."},{"key":"10.1016\/j.bbcan.2026.189637_bb0115","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"issue":"19","key":"10.1016\/j.bbcan.2026.189637_bb0120","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","article-title":"FDA approval summary: Lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1-based immunotherapy","volume":"31","author":"Hu","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0125","first-page":"77","article-title":"Cytokine-induced killer cells: a unique platform for adoptive cell immunotherapy after allogeneic hematopoietic stem cell transplantation","volume":"52","author":"Rettinger","year":"2025","journal-title":"Transfus. Med. Hemother."},{"issue":"6717","key":"10.1016\/j.bbcan.2026.189637_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq7248","article-title":"Cancer immunotherapy by \u03b3\u03b4 T cells","volume":"386","author":"Hayday","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189637_bb0135","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","article-title":"CAR-macrophages in solid tumors: promise, progress, and prospects","volume":"9","author":"Alrehaili","year":"2025","journal-title":"NPJ Precis. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189637_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111128","article-title":"Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy","volume":"40","author":"Chang","year":"2022","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189637_bb0145","doi-asserted-by":"crossref","first-page":"296","DOI":"10.37349\/etat.2024.00219","article-title":"Emerging roles of type 1 innate lymphoid cells in tumor pathogenesis and cancer immunotherapy","volume":"5","author":"Verner","year":"2024","journal-title":"Explor. Target Antitumor Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189637_bb0150","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.cell.2023.12.015","article-title":"Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death","volume":"187","author":"Li","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189637_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.782448","article-title":"Epigenetic priming of bladder cancer cells with decitabine increases cytotoxicity of human EGFR and CD44v6 CAR engineered T-cells","volume":"12","author":"Grunewald","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0350","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/CJI.0000000000000301","article-title":"CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal Cancer models","volume":"43","author":"Li","year":"2020","journal-title":"J. Immunother."},{"key":"10.1016\/j.bbcan.2026.189637_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150781","article-title":"Cabozantinib enhances CAIX specific CAR-T cells against renal cancer by improving effector functions and augmenting tumor immune microenvironment","volume":"734","author":"Li","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189637_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105829","article-title":"Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer","volume":"174","author":"Lu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189637_bb0440","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.omto.2020.07.006","article-title":"Lactate dehydrogenase a depletion alters MyC-CaP tumor metabolism, microenvironment, and CAR T cell therapy","volume":"18","author":"Mane","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189637_bb0445","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","article-title":"Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0475","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12951-022-01635-y","article-title":"Enhanced natural killer cell antitumor activity with nanoparticles mediated ferroptosis and potential therapeutic application in prostate cancer","volume":"20","author":"Kim","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbcan.2026.189637_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.789078","article-title":"Phase I clinical trial of an autologous dendritic cell vaccine against HER2 shows safety and preliminary clinical efficacy","volume":"11","author":"Maeng","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189637_bb0290","first-page":"1709","article-title":"Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy","volume":"11","author":"Wang","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189637_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.779248","article-title":"High complete response rate in patients with metastatic renal cell carcinoma receiving autologous cytokine-induced killer cell therapy plus anti-programmed Death-1 agent: a single-Center study","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189637_bb0370","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5709104","article-title":"Efficacy of enhanced cytokine-induced killer cells as an adjuvant immunotherapy for renal cell carcinoma: preclinical and clinical studies","volume":"2021","author":"Yang","year":"2021","journal-title":"J. Healthc. Eng."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189637_bb0375","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189637_bb0380","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","article-title":"Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma","volume":"26","author":"Figlin","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189637_bb0450","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0465","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005847","article-title":"Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer","volume":"11","author":"Karbach","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189637_bb0455","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF-\u03b2-insensitive armored CAR Tcells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189637_bb0480","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/sctm.18-0230","article-title":"A phase I study to assess the safety and Cancer-homing ability of allogeneic bone marrow-derived mesenchymal stem cells in men with localized prostate cancer","volume":"8","author":"Schweizer","year":"2019","journal-title":"Stem Cells Transl. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0460","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189637_bb0470","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/pros.24267","article-title":"Long-term first-in-man phase I\/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy","volume":"82","author":"Tryggestad","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2026.189637_bb0485","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-3052","article-title":"Phase 1 trial of P-PSMA-101 CAR-T cells in patients with metastatic castration resistant prostate cancer (mCRPC)","author":"Slovin","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189637_bb0155","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189637_bb0160","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","article-title":"Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy","volume":"24","author":"Lu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189637_bb0165","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189637_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111462","article-title":"CAF-secreted LOX promotes PD-L1 expression via histone lactylation and regulates tumor EMT through TGF-\u03b2\/IGF1 signaling in gastric cancer","volume":"124","author":"Li","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bbcan.2026.189637_bb0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ebiom.2019.10.037","article-title":"Lysyl oxidase promotes liver metastasis of gastric cancer via facilitating the reciprocal interactions between tumor cells and cancer associated fibroblasts","volume":"49","author":"Li","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbcan.2026.189637_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.694145","article-title":"TGF-\u03b21 induces immune escape by enhancing PD-1 and CTLA-4 expression on T lymphocytes in hepatocellular carcinoma","volume":"11","author":"Bao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189637_bb0185","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/carcin\/bgaa092","article-title":"Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer","volume":"42","author":"Chatterjee","year":"2021","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2026.189637_bb0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189637_bb0195","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189637_bb0200","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhances MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2026.189637_bb0205","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","article-title":"Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism","volume":"25","author":"Peralta","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2026.189637_bb0215","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","article-title":"Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2026.189637_bb0220","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","article-title":"Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors","volume":"54","author":"Xu","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2026.189637_bb0225","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","article-title":"CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability","volume":"33","author":"Ma","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2026.189637_bb0230","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41419-024-06503-1","article-title":"Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor-infiltrating CD8+ T cells","volume":"15","author":"Han","year":"2024","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189637_bb0235","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/s41590-025-02223-6","article-title":"Early methionine availability attenuates T cell exhaustion","volume":"26","author":"Sharma","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2026.189637_bb0240","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumors","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189637_bb0245","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189637_bb0250","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","article-title":"Lactate and lactylation in cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10364","key":"10.1016\/j.bbcan.2026.189637_bb0255","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.bbcan.2026.189637_bb0260","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.3390\/cancers14133073","article-title":"BCG in bladder cancer immunotherapy","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189637_bb0265","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001673","article-title":"Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo","volume":"8","author":"Bunch","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0270","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1038\/s41598-024-56297-7","article-title":"Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy","volume":"14","author":"Lim","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0275","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13046-024-02955-7","article-title":"High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor","volume":"43","author":"Wang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189637_bb0295","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4797","article-title":"Renal cell carcinoma","volume":"349","author":"Jonasch","year":"2014","journal-title":"BMJ"},{"issue":"5413","key":"10.1016\/j.bbcan.2026.189637_bb0300","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.284.5413.455","article-title":"Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function","volume":"284","author":"Stebbins","year":"1999","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"Pt 3","key":"10.1016\/j.bbcan.2026.189637_bb0310","article-title":"Comprehensive pan-cancer analysis reveals CD70 as a promising therapeutic target and biomarker in clear cell renal cell carcinoma","volume":"307","author":"Zhang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"14","key":"10.1016\/j.bbcan.2026.189637_bb0315","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","article-title":"Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma","volume":"82","author":"Panowski","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0320","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12967-024-05101-1","article-title":"The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment","volume":"22","author":"Xiong","year":"2024","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189637_bb0325","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s12094-024-03792-y","article-title":"Development of B7-H3 targeted CAR-T cells for renal cell carcinoma therapy: in vitro and in vivo efficacy","volume":"27","author":"Deng","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bbcan.2026.189637_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2024.10.006","article-title":"Preclinical assessment of the efficacy of B7-H3 CAR-T in renal cell carcinoma","volume":"176","author":"Li","year":"2024","journal-title":"Mol. Immunol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189637_bb0335","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.3390\/ijms23105448","article-title":"Immune checkpoint blockade via PD-L1 potentiates more CD28-based than 4-1BB-based anti-carbonic anhydrase IX chimeric antigen receptor T cells","volume":"23","author":"de Campos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189637_bb0340","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.omto.2021.12.019","article-title":"Anti-CAIX BB\u03b6 CAR4\/8 T cells exhibit superior efficacy in a ccRCC mouse model","volume":"24","author":"Wang","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189637_bb0345","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","article-title":"GLUT1 overexpression enhances CAR T cell metabolic fitness and antitumor efficacy","volume":"32","author":"Shi","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2026.189637_bb0385","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omto.2022.06.007","article-title":"Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer","volume":"26","author":"Jin","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0390","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/ijms25010586","article-title":"Comparative evaluation of STEAP1 targeting chimeric antigen receptors with different costimulatory domains and spacers","volume":"25","author":"Jin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0395","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbcan.2026.189637_bb0400","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.omto.2020.06.014","article-title":"PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model","volume":"18","author":"Alzubi","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.bbcan.2026.189637_bb0405","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2021.10.041","article-title":"A highly-specific fully-human antibody and CAR-T cells targeting CD66e\/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo","volume":"525","author":"Baek","year":"2022","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189637_bb0410","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 Signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"22","key":"10.1016\/j.bbcan.2026.189637_bb0415","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169655","article-title":"Antitumor activity of AZD0754, a dnTGF-\u03b2RII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer","volume":"133","author":"Zanvit","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"Pt A","key":"10.1016\/j.bbcan.2026.189637_bb0420","article-title":"Dominant negative TGF-\u03b2 receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer","volume":"124","author":"Tang","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189637_bb0425","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/15384047.2020.1739952","article-title":"Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression","volume":"21","author":"Weimin","year":"2020","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189637_bb0430","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/biomedicines11020459","article-title":"Development of a TGF-\u03b2-IL-2\/15 switch receptor for use in adoptive cell therapy","volume":"11","author":"Beck","year":"2023","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189637_bb0435","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1007\/s00432-022-04248-y","article-title":"Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs","volume":"148","author":"Zhang","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0490","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1038\/s41467-022-33780-1","article-title":"Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease","volume":"13","author":"Wong","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0495","doi-asserted-by":"crossref","first-page":"9949","DOI":"10.1038\/s41467-024-54364-1","article-title":"Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer","volume":"15","author":"Kiviaho","year":"2024","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189637_bb0500","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41571-024-00926-7","article-title":"Spatial landscapes of cancers: insights and opportunities","volume":"21","author":"Chen","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189637_bb0505","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41571-023-00729-2","article-title":"Advancing CAR T cell therapy through the use of multidimensional omics data","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189637_bb0510","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41423-024-01153-x","article-title":"Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy","volume":"21","author":"Zhu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0515","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13046-020-01572-4","article-title":"Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers","volume":"39","author":"Loureiro","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189637_bb0520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","article-title":"The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells","volume":"211","author":"Bachmann","year":"2019","journal-title":"Immunol. Lett."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189637_bb0525","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41551-023-01102-5","article-title":"Control of the antitumor activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumor cells","volume":"8","author":"Stepanov","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"44","key":"10.1016\/j.bbcan.2026.189637_bb0530","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2405085121","article-title":"Dual ON\/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs","volume":"121","author":"Giordano Attianese","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189637_bb0535","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1039\/D4QM00479E","article-title":"Critical considerations of mRNA-LNP technology for CAR-T therapy: components, payloads and emerging horizons","volume":"8","author":"Qu","year":"2024","journal-title":"Mater. Chem. Front."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189637_bb0540","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/bloodadvances.2023012240","article-title":"\u201cDon\u2019t keep me waiting\u201d: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes","volume":"8","author":"Vadgama","year":"2024","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189637_bb0545","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2026.189637_bb0550","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-cancerbio-062822-023316","article-title":"Allogeneic CAR T cell therapy for cancer","volume":"8","author":"Sasu","year":"2024","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.bbcan.2026.189637_bb0555","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1457629","article-title":"Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy","volume":"15","author":"Fang","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189637_bb0560","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/cells9061382","article-title":"Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer","volume":"9","author":"Montagner","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189637_bb0565","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/cac2.12321","article-title":"The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death","volume":"42","author":"Wu","year":"2022","journal-title":"Cancer Commun. (Lond.)"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189637_bb0570","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.3390\/ijms21114118","article-title":"Mouse tumor models for advanced cancer immunotherapy","volume":"21","author":"Chulpanova","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189637_bb0575","first-page":"153","article-title":"PDX models for functional precision oncology and discovery science","volume":"25","author":"Blanchard","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189637_bb0580","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189637_bb0585","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189637_bb0590","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: modelling the complexity of the tumor immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189637_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1378944","article-title":"Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives","volume":"15","author":"Levstek","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:22:51Z","timestamp":1789518171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":118,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0304419X26001095"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189637","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status, prospects, and challenges of cell therapy for urological tumors","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189637"}}